Ascentage Pharma Group International - American Depository Shares

Positives: 353.2 million dollars of cash at December 31, 2025 after the U.S. IPO and a July 2025 top‑up placement provides liquidity. The company improved 2024 operating cash outflow to roughly 111 million RMB (about 15 million dollars), reflecting the Takeda payment year, but 2025 losses widened as R&D and commercial spending increased.

Leverage: interest‑bearing borrowings were about 1.72 billion RMB mid‑2025, partially offset by cash. Net FCF remains negative on a TTM basis, making continued capital access and non‑dilutive BD important. We view the balance sheet as adequate for near‑term plans but not yet robust against multi‑year setbacks.